

# Jun Guo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8023282/publications.pdf>

Version: 2024-02-01

103  
papers

2,548  
citations

361413

20  
h-index

206112

48  
g-index

104  
all docs

104  
docs citations

104  
times ranked

3362  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. <i>Clinical Cancer Research</i> , 2022, 28, 489-497.	7.0	36
2	Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	4
3	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
4	ASO Author Reflections: Staging System for Mucosal Melanoma: A Proposal to Fill a Gap. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
5	Evolving Treatment Approaches to Mucosal Melanoma. <i>Current Oncology Reports</i> , 2022, 24, 1261-1271.	4.0	7
6	Anti-LAG-3 antibody LBL-007 in combination with toripalimab in patients with unresectable or metastatic melanoma: A phase â..., open-label, multicenter, dose escalation/expansion study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9538-9538.	1.6	2
7	Ratio of the interferon-Î³ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	3.8	41
8	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 881-889.	1.6	37
9	Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapyâ€™ Ad hoc Analyses of Pooled Data From Two Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 639085.	2.8	6
10	RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4534-4534.	1.6	10
11	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. <i>Frontiers in Immunology</i> , 2021, 12, 680407.	4.8	68
12	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. <i>Frontiers in Pharmacology</i> , 2021, 12, 747416.	3.5	0
13	Surgical Outcomes of Vaginal or Cervical Melanoma. <i>Frontiers in Surgery</i> , 2021, 8, 771160.	1.4	1
14	Toripalimab for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 863-869.	3.1	15
15	Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 135, 31-38.	2.8	11
16	MUC4 isoforms expression profiling and prognosis value in Chinese melanoma patients. <i>Clinical and Experimental Medicine</i> , 2020, 20, 299-311.	3.6	7
17	Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10007-10007.	1.6	11
18	Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10020-10020.	1.6	2

#	ARTICLE	IF	CITATIONS
19	A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.. Journal of Clinical Oncology, 2020, 38, 10040-10040.	1.6	10
20	A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10047-10047.	1.6	5
21	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2020, 38, e17113-e17113.	1.6	9
22	PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, TPS763-TPS763.	1.6	15
23	IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/1b study.. Journal of Clinical Oncology, 2020, 38, e15111-e15111.	1.6	1
24	Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy.. Journal of Clinical Oncology, 2020, 38, e22043-e22043.	1.6	1
25	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 6511-6523.	7.0	62
26	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of Clinical Oncology, 2019, 37, 2987-2999.	1.6	126
27	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
28	miR-let-7b and miR-let-7c suppress tumorigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. Journal of Experimental and Clinical Cancer Research, 2019, 38, 212.	8.6	53
29	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). Translational Oncology, 2019, 12, 828-835.	3.7	90
30	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology and Oncology, 2019, 12, 7.	17.0	113
31	A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 4509-4509.	1.6	32
32	Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.. Journal of Clinical Oncology, 2019, 37, 9528-9528.	1.6	7
33	A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4595-TPS4595.	1.6	3
34	Mucosal melanoma staging and classification: Firstly established.. Journal of Clinical Oncology, 2019, 37, e21008-e21008.	1.6	0
35	Postoperative radiotherapy in resected sinonasal mucosal melanoma.. Journal of Clinical Oncology, 2019, 37, e21059-e21059.	1.6	0
36	Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma. Future Oncology, 2018, 14, 1835-1845.	2.4	4

#	ARTICLE	IF	CITATIONS
37	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69.	17.0	32
38	A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9528-9528.	1.6	9
39	A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9539-9539.	1.6	12
40	Phase â...ç randomized, multicenter trial comparing high-dose IFN- $\alpha$ 2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9589-9589.	1.6	18
41	Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16505-e16505.	1.6	3
42	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18609-e18609.	1.6	0
43	EZH2 copy number gain as a therapeutic target in mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21530-e21530.	1.6	1
44	Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4605-TPS4605.	1.6	0
45	Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16588-e16588.	1.6	1
46	Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9588-9588.	1.6	0
47	Sunrise in melanoma management: Time to focus on melanoma burden in Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 423-427.	1.1	23
48	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	27.8	146
49	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6946-6957.	7.0	73
50	Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. <i>Oncology Letters</i> , 2017, 15, 1839-1844.	1.8	12
51	Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. <i>Journal of Translational Medicine</i> , 2017, 15, 243.	4.4	33
52	A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3067-3067.	1.6	1
53	A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4575-4575.	1.6	5
54	Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21055-e21055.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Multivariate analysis of prognostic factors among 706 mucosal melanoma patients.. Journal of Clinical Oncology, 2017, 35, 9569-9569.	1.6	0
56	Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.. Journal of Clinical Oncology, 2017, 35, e21017-e21017.	1.6	4
57	OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.. Journal of Clinical Oncology, 2017, 35, e21013-e21013.	1.6	4
58	Whole genome and RNA sequencing reveal the distinct genomic landscape of acral melanoma.. Journal of Clinical Oncology, 2017, 35, 9589-9589.	1.6	2
59	OrienX010 oncolytic viral therapy in phase Å¢ b trial of intralesional injection in unresected stage Å¢Å¢c to Å¢Å£ acral melanoma patients in China.. Journal of Clinical Oncology, 2016, 34, e21001-e21001.	1.6	2
60	Association of immune-inflammation index with outcome of high-risk acral melanoma patients treated with adjuvant high-dose interferon.. Journal of Clinical Oncology, 2016, 34, e21070-e21070.	1.6	4
61	Imatinib versus interferon as adjuvant therapy in a phase II study in patients with highrisk C-Kit mutated melanoma.. Journal of Clinical Oncology, 2016, 34, e21073-e21073.	1.6	1
62	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 2016, 5, 57-57.	1.2	46
63	The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma.. Journal of Clinical Oncology, 2016, 34, 444-444.	1.6	0
64	Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.. Journal of Clinical Oncology, 2016, 34, 594-594.	1.6	0
65	A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).. Journal of Clinical Oncology, 2016, 34, e21043-e21043.	1.6	0
66	Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy.. Journal of Clinical Oncology, 2016, 34, 9512-9512.	1.6	0
67	A prospective multicenter phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma (NCT01762150).. Journal of Clinical Oncology, 2016, 34, 4559-4559.	1.6	0
68	Chinese guidelines on the management of renal cell carcinoma (2015 edition). Chinese Clinical Oncology, 2016, 5, 12.	1.2	8
69	Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. OncoTargets and Therapy, 2015, 8, 1363.	2.0	14
70	Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations.. Journal of Clinical Oncology, 2015, 33, 9047-9047.	1.6	5
71	Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma.. Journal of Clinical Oncology, 2015, 33, e20087-e20087.	1.6	1
72	Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib.. Journal of Clinical Oncology, 2015, 33, 481-481.	1.6	0

#	ARTICLE	IF	CITATIONS
73	A phase II study of everolimus for advanced melanoma patients with mTOR mutations.. Journal of Clinical Oncology, 2015, 33, e20007-e20007.	1.6	0
74	The efficacy and safety analysis of sunitinib plus temozolomide therapy in patients with metastatic mucosal melanoma.. Journal of Clinical Oncology, 2015, 33, e20043-e20043.	1.6	0
75	Effect of nanosecond pulsed electric fields in combination with everolimus on melanoma.. Journal of Clinical Oncology, 2015, 33, e20102-e20102.	1.6	0
76	Clinical presentation, systemic therapy and prognosis of mucosal melanoma, a study of 463 consecutive cases.. Journal of Clinical Oncology, 2015, 33, e20036-e20036.	1.6	0
77	Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.. Journal of Clinical Oncology, 2015, 33, 9049-9049.	1.6	0
78	A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).. Journal of Clinical Oncology, 2015, 33, e15591-e15591.	1.6	0
79	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma.. Journal of Clinical Oncology, 2015, 33, e20076-e20076.	1.6	0
80	Comparison of clinical presentation and prognosis between acral cutaneous melanoma and non-acral cutaneous melanoma.. Journal of Clinical Oncology, 2015, 33, e20008-e20008.	1.6	0
81	Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 36.	1.2	11
82	Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15556-e15556.	1.6	0
83	Outcome of isolated limb infusion (ILI) treatment for Chinese acral melanoma patients with/without gene mutations.. Journal of Clinical Oncology, 2014, 32, e20014-e20014.	1.6	0
84	Primary malignant melanoma of the esophagus: Clinical features, signaling pathway, management, and survival.. Journal of Clinical Oncology, 2014, 32, e20015-e20015.	1.6	0
85	Effect of restoration of microRNA-18a on improvement of imatinib therapy on secondary imatinib-resistance metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9040-9040.	1.6	0
86	Salvage therapy for metastatic acral or mucosal melanoma: Efficacy and safety analysis of nab-paclitaxel/carboplatin combined with bevacizumab in c-kit/BRAF wild-type pts.. Journal of Clinical Oncology, 2014, 32, e20017-e20017.	1.6	0
87	A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma.. Journal of Clinical Oncology, 2014, 32, e15554-e15554.	1.6	0
88	Prognostic factors for disease-free survival of ethnic Chinese patients with ocularmelanoma.. Journal of Clinical Oncology, 2014, 32, e20016-e20016.	1.6	0
89	Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study. BMC Cancer, 2013, 13, 136.	2.6	26
90	A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma. Molecular Therapy, 2013, 21, 1456-1463.	8.2	88

#	ARTICLE	IF	CITATIONS
91	Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ).. Journal of Clinical Oncology, 2013, 31, 366-366.	1.6	7
92	Hypertension and myelosuppression as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 426-426.	1.6	1
93	Hand-foot syndrome (HFS) and asthenia/fatigue (A/F) as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, e15622-e15622.	1.6	0
94	A phase II randomized study of adjuvant imatinib versus high-dose interferon alpha-2b for resected high-risk c-kit mutated melanoma.. Journal of Clinical Oncology, 2013, 31, e20027-e20027.	1.6	0
95	Phase II randomized study of high-dose interferon alfa-2b (HDI) versus chemotherapy as adjuvant therapy in patients with resected mucosal melanoma.. Journal of Clinical Oncology, 2012, 30, 8506-8506.	1.6	3
96	Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.. Journal of Clinical Oncology, 2012, 30, 8554-8554.	1.6	3
97	Association of the activation of the mTOR pathway with prognosis in Chinese melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8561-8561.	1.6	0
98	mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance.. Journal of Clinical Oncology, 2012, 30, 8562-8562.	1.6	0
99	Primary hypertension to predict progression-free survival of target therapy in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15052-e15052.	1.6	1
100	Association of single nucleotide polymorphisms in AGT, VEGF, and APOE genes with clinical outcome of target therapy in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, e15051-e15051.	1.6	1
101	Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification. Journal of Clinical Oncology, 2011, 29, 2904-2909.	1.6	646
102	Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases. BMC Cancer, 2011, 11, 85.	2.6	276
103	Effects of Compound Dan-shen Root Dropping Pill on hemorheology in high-fat diet induced hyperlipidemia in dogs. Clinical Hemorheology and Microcirculation, 2005, 32, 19-30.	1.7	6